T. Mirzadegan

PROFILE

Homepage
No homepage is listed.
ORCID
No ORCID is listed.
Affiliations
No affiliations are listed.
Aliases
Taraneh Mirzadegan, Taraneh Los Altos Mirzadegan, T Mirzadegan, T. Mirzadegan, Tara Mirzadegan
Publication record
75 papers · 2,967 citations · H-index 26

PAPERS

HUMAN NIK IN COMPLEX WITH LIGAND COMPOUND X
20200 citationsauthor #3
Breaking the Glass Ceiling in Simulation and Modeling: Women in Pharmaceutical Discovery.
20204 citationsauthor #7
A computational approach yields selective inhibitors of human excitatory amino acid transporter 2 (EAAT2)
20202 citationsauthor #5
Impact of Protein Preparation on Resulting Accuracy of FEP Calculations
202015 citationsauthor #3
Accelerating Lead Identification by High Throughput Virtual Screening: Prospective Case Studies from the Pharmaceutical Industry
201928 citationsauthor #11
BTK in complex with inhibitor 8-(2,3-dihydro-1H-inden-5-yl)-2-({4-[(2S)-3-(dimethylamino)-2-hydroxypropoxy]phenyl}amino)-5,8-dihydropteridine-6,7-dione
20190 citationsauthor #1
D3R grand challenge 4: blind prediction of protein–ligand poses, affinity rankings, and relative binding free energies
2019108 citationsauthor #14
BTK in complex with inhibitor N-(3-{[(2,6-dimethylphenyl)methyl]amino}-7-methoxyindeno[1,2-c]pyrazol-6-yl)methanesulfonamide
20190 citationsauthor #2
Hypoxia-Inducible Factor (HIF) Prolyl Hydroxylase 2 (PHD2) in Complex with the Carboxamide Analog JNJ43058171
20190 citationsauthor #2
Beyond Traditional Structure-Based Drug Design: The Role of Iron Complexation, Strain, and Water in the Binding of Inhibitors for Hypoxia-Inducible Factor Prolyl Hydroxylase 2
20195 citationsauthor #9
Dynamic Structural Differences between Human and Mouse STING Lead to Differing Sensitivity to DMXAA.
201878 citationsauthor #3
Determination of a Focused Mini Kinase Panel for Early Identification of Selective Kinase Inhibitors
201815 citationsauthor #3
An Analysis of Different Components of a High-Throughput Screening Library
20189 citationsauthor #5
Predicting the Binding of Fatty Acid Amide Hydrolase Inhibitors by Free Energy Perturbation.
201818 citationsauthor #3
FAAH bound to non covalent inhibitor
20180 citationsauthor #3
Computational chemistry at Janssen
201716 citationsauthor #3
Crystal structure of human Cathepsin-S with bound ligand
20171 citationsauthor #3
HUMAN TNF-ALPHA IN COMPLEX WITH JNJ525
20170 citationsauthor #8
Structural Basis of Small-Molecule Aggregate Induced Inhibition of a Protein-Protein Interaction.
201759 citationsauthor #8
A Single Amino Acid Difference between Mouse and Human 5-Lipoxygenase Activating Protein (FLAP) Explains the Speciation and Differential Pharmacology of Novel FLAP Inhibitors*
20169 citationsauthor #6
A Prospective Virtual Screening Study: Enriching Hit Rates and Designing Focus Libraries To Find Inhibitors of PI3Kδ and PI3Kγ.
201624 citationsauthor #10
Analysis of the Structural and Molecular Basis of Voltage-sensitive Sodium Channel Inhibition by the Spider Toxin Huwentoxin-IV (μ-TRTX-Hh2a)
201363 citationsauthor #7
Identification of Structural Motifs Critical for Epstein-Barr Virus-Induced Molecule 2 Function and Homology Modeling of the Ligand Docking Site
201220 citationsauthor #8
3,5-Dihydroxybenzoic Acid, a Specific Agonist for Hydroxycarboxylic Acid 1, Inhibits Lipolysis in Adipocytes
2012101 citationsauthor #7
Functional Studies of Interaction Between Huwentoxin-IV and Voltage-Gated Sodium Channel Nav1.7
20122 citationsauthor #11
Library Enhancement through the Wisdom of Crowds
201135 citationsauthor #8
Pharmacological characterization of 1-(5-chloro-6-(trifluoromethoxy)-1H-benzoimidazol- 2-yl)-1H-pyrazole-4-carboxylic acid (JNJ-42041935), a potent and selective HIF prolyl hydroxylase (PHD) inhibitor
20112 citationsauthor #19
Study of GPR 81 , the Lactate Receptor , from Distant Species Identifies Residues and Motifs Critical for GPR 81 Functions
20118 citationsauthor #7
Pharmacological Characterization of 1-(5-Chloro-6-(trifluoromethoxy)-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic Acid (JNJ-42041935), a Potent and Selective Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor
201179 citationsauthor #18
Study of GPR81, the Lactate Receptor, from Distant Species Identifies Residues and Motifs Critical for GPR81 Functions
201161 citationsauthor #7
Chimeric, mutant orexin receptors show key interactions between orexin receptors, peptides and antagonists.
201133 citationsauthor #4
Discovery of piperidin-4-yl-aminopyrimidines as HIV-1 reverse transcriptase inhibitors. N-benzyl derivatives with broad potency against resistant mutant viruses.
201065 citationsauthor #9
Highly potent, non-basic 5-HT6 ligands. Site mutagenesis evidence for a second binding mode at 5-HT6 for antagonism.
201042 citationsauthor #10
Benzimidazole-2-pyrazole HIF Prolyl 4-Hydroxylase Inhibitors as Oral Erythropoietin Secretagogues.
201063 citationsauthor #17
Exploration of piperidine-4-yl-aminopyrimidines as HIV-1 reverse transcriptase inhibitors. N-Phenyl derivatives with broad potency against resistant mutant viruses.
201021 citationsauthor #11
Reply to Xu: Role of Lactate in Lipid Metabolism, Just Always Inhibiting Lipolysis?
20090 citationsauthor #10
Lactate Inhibits Lipolysis in Fat Cells through Activation of an Orphan G-protein-coupled Receptor, GPR81*
2009489 citationsauthor #10
Molecular Interactions of CCR5 with Major Classes of Small-Molecule Anti-HIV CCR5 Antagonists
2008192 citationsauthor #4
Design of annulated pyrazoles as inhibitors of HIV-1 reverse transcriptase.
200867 citationsauthor #12
Discovery and optimization of pyridazinone non-nucleoside inhibitors of HIV-1 reverse transcriptase.
200837 citationsauthor #15
Substrate-dependent inhibition or stimulation of HIV RNase H activity by non-nucleoside reverse transcriptase inhibitors (NNRTIs).
200755 citationsauthor #5
CCR5 antagonists have different conformational requirements for the transition to the most thermodynamically stable CCR5 receptor:antagonist complex.
20060 citationsauthor #8
Recent progress in the design of small molecule inhibitors of HIV RNase H.
200671 citationsauthor #2
Possible role of the 11-cis-retinyl conformation in controlling the dual decay processes of excited rhodopsin.
200511 citationsauthor #3
Rational design of 6-methylsulfonylindoles as selective cyclooxygenase-2 inhibitors.
200450 citationsauthor #6
Inhibitors of the non-nucleoside reverse transcriptase inhibitors
20040 citationsauthor #3
Lactams as EP4 prostanoid receptor agonists. 3. Discovery of N-ethylbenzoic acid 2-pyrrolidinones as subtype selective agents.
200426 citationsauthor #10
Sequence analyses of G-protein-coupled receptors: similarities to rhodopsin.
2003377 citationsauthor #1
Chemokine and Cytokine Modulators
20031 citationsauthor #2
Prostaglandin analogs as ep4-receptor agonists
20021 citationsauthor #2
CI-1017, a functionally M1-selective muscarinic agonist: design, synthesis, and preclinical pharmacology.
200012 citationsauthor #10
Identification of the Binding Site for a Novel Class of CCR2b Chemokine Receptor Antagonists
2000250 citationsauthor #1
Design and synthesis of m1-selective muscarinic agonists: (R)-(-)-(Z)-1-Azabicyclo[2.2.1]heptan-3-one, O-(3-(3'-methoxyphenyl)-2-propynyl)oxime maleate (CI-1017), a functionally m1-selective muscarinic agonist.
199824 citationsauthor #12
Crystal structure of phenylmethanesulfonyl fluoride-treated human chymase at 1.9 A.
199752 citationsauthor #2
Aryleneyne 1-azabicyclo[2.2.1]heptan-3-one oximes: Potent muscarinic agonists
19950 citationsauthor #4
(±)-1-Azabicyclo[2.2.1]heptan-3-one, O-(3-methyl-5-aryl-2-penten-4-ynyl) oximes: Potent muscarinic agonists
19954 citationsauthor #4
Z-(±)-1-azabicyclo[2.2.1]heptan-3-one, O-(3-aryl-2-propynyl) oximes as potential m1-subtype selective muscarinic agonists
19955 citationsauthor #7
Mutations of aspartate 103 in the Hm2 receptor and alterations in receptor binding properties of muscarinic agonists.
199515 citationsauthor #4
Azulenic retinoids: novel nonbenzenoid aromatic retinoids with anticancer activity.
199347 citationsauthor #4
Synthesis and SAR of bulky 1-azabicyclo[2.2.1]-3-one oximes as muscarinic receptor subtype selective agonists.
199318 citationsauthor #3
Docking ligands in the receptor cavity: What have we learned?
19933 citationsauthor #3
Molecular modeling studies of the m1 and m2 muscarinic receptors leading to the design of selective m1 agonists
19930 citationsauthor #1
Chapter 30. Three-dimensional Models of G-Protein Coupled Receptors
199219 citationsauthor #2
A rationale for the design and synthesis of m1 selective muscarinic agonists.
19928 citationsauthor #2
Substitution of Lysine‐181 to Aspartic Acid in the Third Transmembrane Region of the Endothelin (ET) Type B Receptor Selectively Reduces Its High‐Affinity Binding with ET‐3 Peptide
19926 citationsauthor #4
MODELING RHODOPSIN, A MEMBER OF G‐PROTEIN COUPLED RECEPTORS, BY COMPUTER GRAPHICS. INTERPRETATION OF CHEMICAL SHIFTS OF FLUORINATED RHODOPSINS
199211 citationsauthor #1
Replacement of lysine‐181 by aspartic acid in the third transmembrane region of endothelin type B receptor reduces its affinity to endothelin peptides and sarafotoxin 6c without affecting G protein coupling
199237 citationsauthor #6
Chapter 3 Probing the visual pigment rhodopsin and its analogs by molecular modeling analysis and computer graphics
19916 citationsauthor #1
New Geometric Isomers of Vitamin A. Part 17. The Doubly Hindered 7,11-Dicis, 7,9,11-Tricis, 7,11,13-Tricis and All-cis Isomers of Retinonitrile and Retinal.
19900 citationsauthor #2
The doubly hindered 7,11-dicis, 7,9,11-tricis, 7,11,13-tricis and all-cis isomers of retinonitrile and retinal☆
199014 citationsauthor #2
Isomers, visual pigment, and bacteriorhodopsin analogs of 3,7,13-trimethyl-10-isopropyl-2,4,6,8,10-tetradecapentaenal and 3,7,11-trimethyl-10-isopropyl-2,4,6,8,10-dodecapentaenal (two ring open retinal analogs)
19896 citationsauthor #4
A study of the binding site requirements of rhodopsin using isomers of α-retinal and 5-substituted α-retinal analogs
198910 citationsauthor #4
Recent Advances in the Synthesis of Retinoids and Visual Pigment Analogs Studies
19890 citationsauthor #2
The shape of a three-dimensional binding site of rhodopsin based on molecular modeling analyses of isomeric and other visual pigment analogues: bioorganic studies of visual pigments. XI
198846 citationsauthor #2
Study of the shape of the binding site of bovine opsin using 10-substituted retinal isomers.
198614 citationsauthor #4

TIMELINE

1986 14 citations

1988 46 citations

1989 16 citations

1990 14 citations

1991 6 citations

1992 81 citations

1993 68 citations

1995 24 citations

1997 52 citations

1998 24 citations

2000 262 citations

2002 1 citations

2003 378 citations

2004 76 citations

2005 11 citations

2006 71 citations

2007 55 citations

2008 296 citations

2009 489 citations

2010 191 citations

2011 218 citations

2012 123 citations

2013 63 citations

2016 33 citations

2017 76 citations

2018 120 citations

2019 141 citations

2020 21 citations

T. Mirzadegan

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT